84 related articles for article (PubMed ID: 18502016)
1. Quantifiable mRNA transcripts for tamoxifen-metabolising enzymes in human endometrium.
Singh MN; Stringfellow HF; Walsh MJ; Ashton KM; Paraskevaidis E; Abdo KR; Martin-Hirsch PL; Phillips DH; Martin FL
Toxicology; 2008 Jul; 249(1):85-90. PubMed ID: 18502016
[TBL] [Abstract][Full Text] [Related]
2. Disturbed expression of phase I and phase II estrogen-metabolizing enzymes in endometrial cancer: lower levels of CYP1B1 and increased expression of S-COMT.
Hevir N; Sinkovec J; Rižner TL
Mol Cell Endocrinol; 2011 Jan; 331(1):158-67. PubMed ID: 20887769
[TBL] [Abstract][Full Text] [Related]
3. FGF2 transcript levels are positively correlated with EGF and IGF-1 in the malignant endometrium.
Soufla G; Sifakis S; Spandidos DA
Cancer Lett; 2008 Feb; 259(2):146-55. PubMed ID: 18006148
[TBL] [Abstract][Full Text] [Related]
4. 17Beta-hydroxysteroid dehydrogenases in human endometrium and its disorders.
Ito K; Utsunomiya H; Suzuki T; Saitou S; Akahira J; Okamura K; Yaegashi N; Sasano H
Mol Cell Endocrinol; 2006 Mar; 248(1-2):136-40. PubMed ID: 16406263
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of the adult stem cell marker Musashi-1 in endometriosis and endometrial carcinoma.
Götte M; Wolf M; Staebler A; Buchweitz O; Kelsch R; Schüring AN; Kiesel L
J Pathol; 2008 Jul; 215(3):317-29. PubMed ID: 18473332
[TBL] [Abstract][Full Text] [Related]
6. Alterations of the K-ras and p53 genes in Tamoxifen-associated endometrial carcinoma.
Fujiwara K; Enomoto T; Fujita M; Kanda T; Fujii S; Ito K; Wakasa K; Ishiko O; Ueda M; Yamaguchi S; Kimura T; Umesaki N
Oncol Rep; 2008 May; 19(5):1293-8. PubMed ID: 18425390
[TBL] [Abstract][Full Text] [Related]
7. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
8. Class I histone deacetylase expression in the human cyclic endometrium and endometrial adenocarcinomas.
Krusche CA; Vloet AJ; Classen-Linke I; von Rango U; Beier HM; Alfer J
Hum Reprod; 2007 Nov; 22(11):2956-66. PubMed ID: 17728353
[TBL] [Abstract][Full Text] [Related]
9. Expression of cytochrome P450 genes encoding enzymes active in the metabolism of tamoxifen in human uterine endometrium.
Hukkanen J; Mäntylä M; Kangas L; Wirta P; Hakkola J; Paakki P; Evisalmi S; Pelkonen O; Raunio H
Pharmacol Toxicol; 1998 Feb; 82(2):93-7. PubMed ID: 9498238
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen DNA damage detected in human endometrium using accelerator mass spectrometry.
Martin EA; Brown K; Gaskell M; Al-Azzawi F; Garner RC; Boocock DJ; Mattock E; Pring DW; Dingley K; Turteltaub KW; Smith LL; White IN
Cancer Res; 2003 Dec; 63(23):8461-5. PubMed ID: 14679010
[TBL] [Abstract][Full Text] [Related]
11. Induction of hepatic drug-metabolising enzymes and tamoxifen metabolite profile in relation to administration route during low-dose treatment in nude rats.
Kisanga ER; Moi LL; Gjerde J; Mellgren G; Lien EA
J Steroid Biochem Mol Biol; 2005 Apr; 94(5):489-98. PubMed ID: 15876414
[TBL] [Abstract][Full Text] [Related]
12. Derivation of a subtype-specific biochemical signature of endometrial carcinoma using synchrotron-based Fourier-transform infrared microspectroscopy.
Kelly JG; Singh MN; Stringfellow HF; Walsh MJ; Nicholson JM; Bahrami F; Ashton KM; Pitt MA; Martin-Hirsch PL; Martin FL
Cancer Lett; 2009 Feb; 274(2):208-17. PubMed ID: 18954939
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiling of tamoxifen-associated uterine cancers: evidence for two molecular classes of endometrial carcinoma.
Ferguson SE; Olshen AB; Viale A; Awtrey CS; Barakat RR; Boyd J
Gynecol Oncol; 2004 Feb; 92(2):719-25. PubMed ID: 14766275
[TBL] [Abstract][Full Text] [Related]
14. Relationship between tamoxifen use and high risk endometrial cancer histologic types.
Bland AE; Calingaert B; Secord AA; Lee PS; Valea FA; Berchuck A; Soper JT; Havrilesky L
Gynecol Oncol; 2009 Jan; 112(1):150-4. PubMed ID: 18937966
[TBL] [Abstract][Full Text] [Related]
15. Endometrial carcinoma following treatment for breast carcinoma in a Nigerian female. A case report and review of the literature.
Abudu EK; Musa O; Adefuye PO; Abdul Kareem FB; Agboola AO; Banjo AA
Niger Postgrad Med J; 2007 Dec; 14(4):355-7. PubMed ID: 18163149
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen-induced adduct formation and cell stress in human endometrial glands.
Andersson H; Helmestam M; Zebrowska A; Olovsson M; Brittebo E
Drug Metab Dispos; 2010 Jan; 38(1):200-7. PubMed ID: 19812351
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen: important considerations of a multi-functional compound with organ-specific properties.
Singh MN; Stringfellow HF; Paraskevaidis E; Martin-Hirsch PL; Martin FL
Cancer Treat Rev; 2007 Apr; 33(2):91-100. PubMed ID: 17178195
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen use and endometrial lesions: hysteroscopic, histological, and immunohistochemical findings in postmenopausal women with breast cancer.
Dibi RP; Zettler CG; Pessini SA; Ayub AV; de Almeida SB; da Silveira GP
Menopause; 2009; 16(2):293-300. PubMed ID: 19034048
[TBL] [Abstract][Full Text] [Related]
19. Expression of acyl-CoA synthetase 5 in human endometrium and in endometrioid adenocarcinomas.
Gassler N; Yang SH; Keith M; Helmke BM; Schirmacher P; Obermüller N
Histopathology; 2005 Nov; 47(5):501-7. PubMed ID: 16241998
[TBL] [Abstract][Full Text] [Related]
20. Formation of tamoxifen-DNA adducts in human endometrial explants exposed to alpha-hydroxytamoxifen.
Kim SY; Suzuki N; Laxmi YR; McGarrigle BP; Olson JR; Sharma M; Sharma M; Shibutani S
Chem Res Toxicol; 2005 May; 18(5):889-95. PubMed ID: 15892583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
